BioAgilytix, a provider of contract bioanalytical testing services specializing in large molecule bioanalysis, said today it has acquired IPM Biotech for an undisclosed price.
BioAgilytix said the deal will combine IPM’s immunogenicity, pharmacokinetics (PK), and pharmacodynamics (PD) expertise with BioAgilytix’s complementary capabilities in immunogenicity and PK, as well as biomarkers and cell-based assays.
Headquartered in Durham, NC, BioAgilytix offers assay development, validation, and sample analysis under non-GLP, spirit-of-GLP, and GLP, as well as product release testing under GMP.
The acquisition will also expand the buyer’s global presence, with IPM’s planned GLP laboratory facility to serve as BioAgilytix’s European headquarters. The new site, BioAlilytix said, will add GMP certification, and expand IPM’s capacity to more than triple its size by year’s end.
“When completed this fall, IPM’s new facility will be the most technologically advanced bioanalytical laboratory in Europe supporting biotherapeutics development,” BioAgilytix CEO Jim Datin declared in a statement. “We will be duplicating the expert resources and extensive platforms already available in BioAgilytix’s premier U.S. laboratory.
Based in Hamburg, Germany, IPM Biotech is a bioanalytical contract research laboratory specializing in immune mediated diseases and disorders.
BioAgilityx said the deal will strengthen its support for new and existing customers—which according to the company include 21 of the top 25 global biopharmas.
“The addition of IPM’s deep scientific expertise and European presence will enable us to more easily support these customers, and new global clients, who have sites on both continents – particularly in Phase II and III trials,” added BioAgilytix founder and CEO Afshin Safavi, Ph.D.